Home > Insider Trading > Filing (0001385508-19-000039)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1385508	Opiant Pharmaceuticals Inc.	OPNT	Metal Mining (1000)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1656633	Roger Crystal	C/O Opiant Pharmaceuticals, Inc. 201 Santa Monica Blvd, Suite 500 Santa Monica CA 90401	Chief Executive Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-04-05	21,472	$7.25	37,248	No	4	M	Direct
Common Stock	Disposition	2019-04-05	16,001	$11.98	21,247	No	4	S	Direct
Common Stock	Disposition	2019-04-08	12,772	$12.10	8,475	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option	Disposition	2019-04-05	21,472	$7.25	21,472	$7.25

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
375,000	2015-10-27	2025-10-26	No	4	M	Direct

Footnotes

The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $11.90 to $12.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $12.06 to $12.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date.